In addition, PRL-3 promotes cell cycle progression and enhances the anti-apoptotic mechanism of tumor cells to achieve drug resistance by upregulating cyclin D1 and CDK2, as well as activating STAT5 and AKT [81]. Here, PTP4A3 is linked to neoplasm.